Serum levels of monocyte chemoattractant protein-1 and all-cause and cardiovascular mortality among patients with coronary artery disease

PloS One
Ding DingWenhua Ling

Abstract

Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine at multiple phases of atherosclerosis in animals, but human studies are few and inconsistent. The aim of this study is to investigate the association of serum MCP-1 with all-cause and cardiovascular disease (CVD) mortality among coronary artery disease (CAD) patients and determine whether this biomarker can add secondary prognostic value to standard risk predictors. MCP-1 was measured at baseline in 1411 CAD patients who were 40-85 years of age. Cox proportional hazards regression models were used to estimate the association of MCP-1 levels with death risk. During a median follow-up of 3.3 years, 117 deaths were recorded, 88 of which were due to CVD. The multivariable-adjusted hazard ratios across tertiles of MCP-1 were 1.51 (95% confidence intervals [CI] 0.89-2.58), 1.00, and 2.11 (95% CI 1.31-3.40) for all-cause mortality, and 1.50 (95% CI 0.80-2.81), 1.00, and 2.21 (95% CI 1.27-3.87) for CVD mortality. The addition of serum MCP-1 to the fully adjusted model increased the C-index by 0.009 (p<0.0001) for all-cause mortality and 0.008 (p<0.0001) for CVD mortality and significantly improved the predictive ability by 12.1% (P = 0.006) on all-cause mortality and ...Continue Reading

References

Oct 1, 1991·The Journal of Clinical Investigation·N A NelkenJ N Wilcox
Jun 1, 1995·Circulation·P Libby
Mar 7, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·F CipolloneA Mezzetti
Sep 5, 2001·International Journal of Cardiology·E EconomouP Toutouzas
Feb 28, 2002·Cardiovascular Research·Stefan StörkPeter Angerer
Feb 4, 2005·Toxicological Sciences : an Official Journal of the Society of Toxicology·Pei-Chung LeeTe-Chang Lee
Apr 22, 2005·The New England Journal of Medicine·Göran K Hansson
Jul 16, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Takayuki SakamotoYukio Maruyama
Aug 16, 2006·Annals of Internal Medicine·Andrew S LeveyUNKNOWN Chronic Kidney Disease Epidemiology Collaboration
Nov 27, 2007·Journal of the American College of Cardiology·James A de LemosEugene Braunwald
Jul 23, 2008·Perspectives in Vascular Surgery and Endovascular Therapy·Kimon Bekelis, Nicos Labropoulos
Jun 10, 2010·Circulation·Matthias NahrendorfFilip K Swirski
Oct 4, 2013·Diabetes Care·Ding DingWenhua Ling

❮ Previous
Next ❯

Citations

Dec 20, 2018·Clinical Hemorheology and Microcirculation·Anne Krüger-GengeFriedrich Jung
Aug 16, 2016·Molecular Nutrition & Food Research·Alejandra SerranoMaría Luisa Ojeda
Jul 6, 2019·Disease Markers·Mihaela MocanAnca Daniela Farcas
Feb 6, 2021·International Journal of Molecular Sciences·Sebastian Dommel, Matthias Blüher
Dec 16, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Paola Caroline Lacerda LeocádioJacqueline Isaura Alvarez-Leite
Mar 20, 2020·Current Vascular Pharmacology·Dimitrios PatouliasCharles Faselis

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass
percutaneous transluminal coronary angioplasty

Software Mentioned

SAS
R
SPSS
CellQuest
FlowCytomix

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.